Rheumatoid arthritis (RA) is a multifactorial autoimmune disease of unknown etiology,
primarily affecting the joints, then extra-articular manifestations can occur. Due to its …

Rheumatoid arthritis (RA) is a heterogeneous autoimmune inflammatory disorder defined by
the damage to the bone and cartilage in the synovium, which causes joint impairment and …

Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, inflammatory disorder that
affects synovial joints, both small and large joints, in a symmetric pattern. This disorder …

Success with B cell depletion using rituximab has proven the concept that B lineage cells
represent a valid target for the treatment of autoimmune diseases, and has promoted the …

Rheumatoid arthritis (RA) is a chronic inflammatory disease with autoimmune pathogenesis.
It affects mainly small joints (of the hands and feet) and has many systemic manifestations …

Rituximab (RTX) is an approved treatment for rheumatoid arthritis (RA) patients that do not
respond adequately to disease-modifying antirheumatic drugs. However, different new …

Co-ordinated interaction between distinct cell types is a hallmark of successful immune
function. A striking example of this is the carefully orchestrated cooperation between helper …

Objective The first biomarker associated with the rheumatoid arthritis is rheumatoid factor
(RF) and since the earliest reports a role has been proposed in the diagnosis and in the …

Objectives. To review studies that address prediction of response to biologic treatment in RA
and to explore the clinical utility of the studied (bio) markers. Methods. A search for relevant …

Objective To identify if rheumatoid factor (RF) is predictor of response to rituximab (RTX),
abatacept (ABT), and tocilizumab (TCZ) in rheumatoid arthritis (RA). Methods Systematic …